157 related articles for article (PubMed ID: 23913314)
1. A case of Fabry nephropathy with histological features of oligonephropathy.
Nishida M; Kosaka K; Hasegawa K; Nishikawa K; Itoi T; Tsukimura T; Togawa T; Sakuraba H; Hamaoka K
Eur J Pediatr; 2014 Aug; 173(8):1111-4. PubMed ID: 23913314
[TBL] [Abstract][Full Text] [Related]
2. Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort.
Maruyama H; Taguchi A; Mikame M; Izawa A; Morito N; Izaki K; Seto T; Onishi A; Sugiyama H; Sakai N; Yamabe K; Yokoyama Y; Yamashita S; Satoh H; Toyoda S; Hosojima M; Ito Y; Tazawa R; Ishii S
Curr Issues Mol Biol; 2021 Jun; 43(1):389-404. PubMed ID: 34205365
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report.
Chong Y; Kim M; Koh ES; Shin SJ; Kim HS; Chung S
BMC Med Genet; 2016 Oct; 17(1):76. PubMed ID: 27776503
[TBL] [Abstract][Full Text] [Related]
4. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
5. Screening for Fabry Disease in Japanese Patients with Young-Onset Stroke by Measuring α-Galactosidase A and Globotriaosylsphingosine.
Kinoshita N; Hosomi N; Matsushima H; Nakamori M; Yagita Y; Yamawaki T; Torii T; Kitamura T; Sueda Y; Shimomura R; Araki M; Nezu T; Aoki S; Ishii S; Maruyama H; Matsumoto M; Maruyama H
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3563-3569. PubMed ID: 30201457
[TBL] [Abstract][Full Text] [Related]
6. Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.
Maruyama H; Takata T; Tsubata Y; Tazawa R; Goto K; Tohyama J; Narita I; Yoshioka H; Ishii S
Clin J Am Soc Nephrol; 2013 Apr; 8(4):629-36. PubMed ID: 23307880
[TBL] [Abstract][Full Text] [Related]
7. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
Politei J; Alberton V; Amoreo O; Antongiovanni N; Arán MN; Barán M; Cabrera G; Di Pietrantonio S; Durand C; Fainboim A; Frabasil J; Pizarro FG; Iotti R; Liern M; Perretta F; Ripeau D; Toniolo F; Trimarchi H; Rivas DV; Wallace E; Schenone AB
Pediatr Nephrol; 2018 Nov; 33(11):2095-2101. PubMed ID: 29987457
[TBL] [Abstract][Full Text] [Related]
8. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
9. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
10. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
11. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
12. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
14. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
16. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
17. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
18. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
Nowak A; Mechtler TP; Desnick RJ; Kasper DC
Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
[TBL] [Abstract][Full Text] [Related]
19. Mutant α-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level.
Mitobe S; Togawa T; Tsukimura T; Kodama T; Tanaka T; Doi K; Noiri E; Akai Y; Saito Y; Yoshino M; Takenaka T; Saito S; Ohno K; Sakuraba H
Mol Genet Metab; 2012 Nov; 107(3):623-6. PubMed ID: 22841442
[TBL] [Abstract][Full Text] [Related]
20. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
